|
Apr 1
|
UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
|
|
Apr 1
|
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
|
|
Apr 1
|
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
|
|
Jan 12
|
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
|
|
Jan 10
|
3 No-Brainer Stocks to Buy With $20 Right Now
|
|
Dec 29
|
Corcept loses patent spat against Teva, shares tumble
|
|
Dec 29
|
UPDATE 2-Corcept loses patent spat against Teva, shares tumble
|
|
Dec 28
|
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 26
|
HSBC Sees Opportunity in These 2 Biopharma Giants Ahead of the 2024 Elections
|
|
Dec 21
|
Here’s Why Teva Pharmaceutical Industries Limited (TEVA) Rose in Q3
|
|
Dec 7
|
FTC warns pharma companies on excessive drug patenting
|
|
Dec 6
|
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
|
|
Nov 30
|
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
|
|
Nov 27
|
Teva Pharmaceutical upgraded to 'Buy' at UBS
|
|
Nov 27
|
Roku upgraded, Lucid Group downgraded: Wall Street's top analyst calls
|
|
Nov 27
|
Teva Pharmaceutical: Long-Term Cash Cow
|
|
Nov 27
|
Midday movers: Affirm, Amazon, and More
|
|
Nov 27
|
Roku raised to Buy, YPF extends gains following upgrade: 4 big analyst picks
|
|
Oct 10
|
UPDATE 1-Drugmaker Teva does not see big impact on business from Israel-Hamas war
|
|
Oct 6
|
Health Care Roundup: Market Talk
|